Ascentage Pharma-B (06855.HK) Sets 25 Mar 2026 Board Meeting to Approve FY2025 Results and Consider Final Dividend

Bulletin Express

Mar 13

Ascentage Pharma Group International (stock code: 06855, “Ascentage Pharma-B”) announced that its board of directors will convene on 25 March 2026. The agenda includes:

• Approval of the audited financial results for the financial year ended 31 December 2025. • Consideration of a potential final dividend for shareholders.

The notice, dated 13 March 2026, was issued by Chairman and Executive Director Dr. Yang Dajun from Suzhou, China.

Board composition at the time of the announcement: • Executive Director: Dr. Yang Dajun • Non-Executive Directors: Dr. Wang Shaomeng, Dr. Lu Simon Dazhong (meets U.S. SEC and Nasdaq independence requirements) • Independent Non-Executive Directors: Mr. Ye Changqing, Mr. Ren Wei, Dr. David Sidransky (Lead Independent Director), Ms. Marina S. Bozilenko, Dr. Debra Yu, and Dr. Marc E. Lippman.

Investors will receive the company’s full-year 2025 performance details and any dividend decision following the board’s deliberations on the stated date.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1180605444"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1180605444\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1180605444?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-13 23:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1180605444","market":"hk","top_or_hot":-1,"title":"Ascentage Pharma-B (06855.HK) Sets 25 Mar 2026 Board Meeting to Approve FY2025 Results and Consider Final Dividend","media":"Bulletin Express","content":"<p>Ascentage Pharma Group International (stock code: 06855, “Ascentage Pharma-B”) announced that its board of directors will convene on 25 March 2026. The agenda includes:</p>\n<p>• Approval of the audited financial results for the financial year ended 31 December 2025.  \n• Consideration of a potential final dividend for shareholders.</p>\n<p>The notice, dated 13 March 2026, was issued by Chairman and Executive Director Dr. Yang Dajun from Suzhou, China.</p>\n<p>Board composition at the time of the announcement:\n• Executive Director: Dr. Yang Dajun  \n• Non-Executive Directors: Dr. Wang Shaomeng, Dr. Lu Simon Dazhong (meets U.S. SEC and Nasdaq independence requirements)  \n• Independent Non-Executive Directors: Mr. Ye Changqing, Mr. Ren Wei, Dr. David Sidransky (Lead Independent Director), Ms. Marina S. Bozilenko, Dr. Debra Yu, and Dr. Marc E. Lippman.</p>\n<p>Investors will receive the company’s full-year 2025 performance details and any dividend decision following the board’s deliberations on the stated date.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ascentage Pharma-B (06855.HK) Sets 25 Mar 2026 Board Meeting to Approve FY2025 Results and Consider Final Dividend</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAscentage Pharma-B (06855.HK) Sets 25 Mar 2026 Board Meeting to Approve FY2025 Results and Consider Final Dividend\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-13 23:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Ascentage Pharma Group International (stock code: 06855, “Ascentage Pharma-B”) announced that its board of directors will convene on 25 March 2026. The agenda includes:</p>\n<p>• Approval of the audited financial results for the financial year ended 31 December 2025.  \n• Consideration of a potential final dividend for shareholders.</p>\n<p>The notice, dated 13 March 2026, was issued by Chairman and Executive Director Dr. Yang Dajun from Suzhou, China.</p>\n<p>Board composition at the time of the announcement:\n• Executive Director: Dr. Yang Dajun  \n• Non-Executive Directors: Dr. Wang Shaomeng, Dr. Lu Simon Dazhong (meets U.S. SEC and Nasdaq independence requirements)  \n• Independent Non-Executive Directors: Mr. Ye Changqing, Mr. Ren Wei, Dr. David Sidransky (Lead Independent Director), Ms. Marina S. Bozilenko, Dr. Debra Yu, and Dr. Marc E. Lippman.</p>\n<p>Investors will receive the company’s full-year 2025 performance details and any dividend decision following the board’s deliberations on the stated date.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06855","symbol_name":"亚盛医药-B","start_time":0,"source_url":"","article_id":"1180605444","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1180605444","pubTimestamp":1773416450,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Ascentage Pharma Group International (stock code: 06855, “Ascentage Pharma-B”) announced that its board of directors will convene on 25 March 2026. The agenda includes: • Approval of the audited...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06855":"亚盛医药-B"},"translate_title":"亚盛医药-B(06855.HK)定于2026年3月25日召开董事会批准2025财年业绩并考虑末期股息","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06855":1},"content_text":"Ascentage Pharma Group International (stock code: 06855, “Ascentage Pharma-B”) announced that its board of directors will convene on 25 March 2026. The agenda includes:\n• Approval of the audited financial results for the financial year ended 31 December 2025.  \n• Consideration of a potential final dividend for shareholders.\nThe notice, dated 13 March 2026, was issued by Chairman and Executive Director Dr. Yang Dajun from Suzhou, China.\nBoard composition at the time of the announcement:\n• Executive Director: Dr. Yang Dajun  \n• Non-Executive Directors: Dr. Wang Shaomeng, Dr. Lu Simon Dazhong (meets U.S. SEC and Nasdaq independence requirements)  \n• Independent Non-Executive Directors: Mr. Ye Changqing, Mr. Ren Wei, Dr. David Sidransky (Lead Independent Director), Ms. Marina S. Bozilenko, Dr. Debra Yu, and Dr. Marc E. Lippman.\nInvestors will receive the company’s full-year 2025 performance details and any dividend decision following the board’s deliberations on the stated date.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}